The U.S. IPO market is no longer frozen for life sciences companies; it is open, albeit selectively. A track record of strong 2026 IPOs is bringing credible issuers back to market, but investors are still demanding maturity, data and discipline. At the same time, the SEC’s pending registered offering and filer-status reforms could give newly public life sciences companies a materially better capital raising toolkit, if adopted, and provide additional tailwinds to the market….
By: Foley Hoag LLP – Public Companies & the Law
By: Foley Hoag LLP – Public Companies & the Law
